The SU2C-SARC032 study evaluating pembrolizumab plus radiotherapy and surgery found the regimen was well tolerated with infrequent surgical complications.
Neoadjuvant pembrolizumab (Keytruda) in combination with radiotherapy and surgery enhanced disease-free survival (DFS) compared with placebo for patients with stage III undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma of the extremity, according to findings from the phase 2 SU2C-SARC032 (NCT03092323) trial published in The Lancet.1
Data revealed that the pembrolizumab regimen demonstrated a 39% improvement in DFS (HR, 0.61; 90% CI, 0.39-0.96). The 2-year DFS benefit in the pembrolizumab group was 67% (90% CI, 58%-78%) vs 52% (90% CI, 42%-62%) in the control group (one-sided stratified log-rank P = .035).
“SU2C-SARC032 is, to our knowledge, the first…